Dybly Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Investors
  • 2

Dybly General Information

Description

Developer of pharmaceutical intended for inflammatory and fibrotic disease patients. The company manufactures several molecules with interesting activity and safety profiles backed by hypothesis-driven small molecule drug design with validation by empirical data, enabling patients with fibrotic diseases, blood cancer, rheumatoid arthritis to get a better cure.

Contact Information

Website
www.dybly.com
Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • Im Erasmushaus
  • Baeumleingasse 18
  • 4051 Basel
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Dybly Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) Completed Startup
2. Angel (individual) 01-Jan-2008 Completed Startup
1. Angel (individual) 01-Dec-2006 Completed Startup
To view Dybly’s complete valuation and funding history, request access »

Dybly Patents

Dybly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200231598-A1 Preparation of condensed triazepine derivatives and their use as bet inhibitors Granted 13-Jun-2018 0000000000
US-10906917-B2 Preparation of condensed triazepine derivatives and their use as bet inhibitors Active 13-Jun-2018 0000000000
CA-3102178-A1 Preparation of condensed triazepine derivatives and their use as bet inhibitors Pending 13-Jun-2018 0000000000
AU-2019284971-A1 Preparation of condensed triazepine derivatives and their use as bet inhibitors Pending 13-Jun-2018 0000000000
EP-3806860-A1 Preparation of condensed triazepine derivatives and their use as bet inhibitors Pending 13-Jun-2018 C07D495/14

Dybly Executive Team (3)

Name Title Board Seat Contact Info
Barbara Staehelin Co-Founder & Chief Executive Officer
Herman Kempen Ph.D Co-Founder & Chief Scientific Officer
Rolf Jan Rutten Co-Founder
To view Dybly’s complete executive team members history, request access »

Dybly Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Eva Capital Accelerator/Incubator Minority 000 0000 000000 0
BioBac Angel Group Minority 000 0000 000000 0
To view Dybly’s complete investors history, request access »